Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SDCBP

Gene summary for SDCBP

Gene summary.

Gene information	Species	Human
	Gene symbol	SDCBP
	Gene ID	6386
	Gene name	syndecan binding protein
	Gene Alias	MDA-9
	Cytomap	8q12.1
	Gene Type	protein-coding
	GO ID	GO:0000122
	UniProtAcc	A0A024R7Z5

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6386	SDCBP	GSM4909285	Human	Breast	IDC	3.32e-05	-2.56e-01	0.21
6386	SDCBP	GSM4909286	Human	Breast	IDC	2.74e-11	-4.68e-01	0.1081
6386	SDCBP	GSM4909290	Human	Breast	IDC	8.18e-18	-6.68e-01	0.2096
6386	SDCBP	GSM4909293	Human	Breast	IDC	4.15e-12	-3.04e-01	0.1581
6386	SDCBP	GSM4909294	Human	Breast	IDC	9.47e-04	-3.55e-01	0.2022
6386	SDCBP	GSM4909296	Human	Breast	IDC	8.42e-29	-6.60e-01	0.1524
6386	SDCBP	GSM4909297	Human	Breast	IDC	4.15e-18	-4.88e-01	0.1517
6386	SDCBP	GSM4909298	Human	Breast	IDC	1.53e-29	-6.69e-01	0.1551
6386	SDCBP	GSM4909301	Human	Breast	IDC	1.82e-10	-4.70e-01	0.1577
6386	SDCBP	GSM4909302	Human	Breast	IDC	3.32e-07	-4.60e-01	0.1545
6386	SDCBP	GSM4909307	Human	Breast	IDC	6.93e-21	-6.26e-01	0.1569
6386	SDCBP	GSM4909308	Human	Breast	IDC	4.81e-09	-4.96e-01	0.158
6386	SDCBP	GSM4909309	Human	Breast	IDC	5.83e-11	-5.30e-01	0.0483
6386	SDCBP	GSM4909311	Human	Breast	IDC	2.14e-40	-6.79e-01	0.1534
6386	SDCBP	GSM4909312	Human	Breast	IDC	4.83e-06	-2.38e-01	0.1552
6386	SDCBP	GSM4909313	Human	Breast	IDC	7.88e-04	-3.82e-01	0.0391
6386	SDCBP	GSM4909317	Human	Breast	IDC	8.49e-05	-4.06e-01	0.1355
6386	SDCBP	GSM4909319	Human	Breast	IDC	6.98e-38	-5.15e-01	0.1563
6386	SDCBP	GSM4909320	Human	Breast	IDC	1.18e-12	-7.27e-01	0.1575
6386	SDCBP	GSM4909321	Human	Breast	IDC	4.38e-22	-5.15e-01	0.1559

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00098956	Stomach	GC	negative regulation of catabolic process	32/1159	320/18723	5.15e-03	4.06e-02	32
GO:004586111	Stomach	CAG with IM	negative regulation of proteolysis	45/1050	351/18723	1.90e-07	1.24e-05	45
GO:004217611	Stomach	CAG with IM	regulation of protein catabolic process	44/1050	391/18723	8.71e-06	2.99e-04	44
GO:190336211	Stomach	CAG with IM	regulation of cellular protein catabolic process	32/1050	255/18723	1.69e-05	5.30e-04	32
GO:003287211	Stomach	CAG with IM	regulation of stress-activated MAPK cascade	25/1050	192/18723	7.51e-05	1.78e-03	25
GO:007030211	Stomach	CAG with IM	regulation of stress-activated protein kinase signaling cascade	25/1050	195/18723	9.68e-05	2.19e-03	25
GO:200005811	Stomach	CAG with IM	regulation of ubiquitin-dependent protein catabolic process	22/1050	164/18723	1.28e-04	2.64e-03	22
GO:003109811	Stomach	CAG with IM	stress-activated protein kinase signaling cascade	29/1050	247/18723	1.37e-04	2.79e-03	29
GO:003243411	Stomach	CAG with IM	regulation of proteasomal ubiquitin-dependent protein catabolic process	19/1050	134/18723	1.74e-04	3.33e-03	19
GO:005140311	Stomach	CAG with IM	stress-activated MAPK cascade	28/1050	239/18723	1.84e-04	3.49e-03	28
GO:190305011	Stomach	CAG with IM	regulation of proteolysis involved in cellular protein catabolic process	26/1050	221/18723	2.88e-04	4.99e-03	26
GO:003133011	Stomach	CAG with IM	negative regulation of cellular catabolic process	29/1050	262/18723	3.76e-04	6.04e-03	29
GO:000660511	Stomach	CAG with IM	protein targeting	33/1050	314/18723	3.98e-04	6.38e-03	33
GO:006113611	Stomach	CAG with IM	regulation of proteasomal protein catabolic process	22/1050	187/18723	8.18e-04	1.08e-02	22
GO:200005911	Stomach	CAG with IM	negative regulation of ubiquitin-dependent protein catabolic process	9/1050	48/18723	1.23e-03	1.48e-02	9
GO:00104986	Stomach	CAG with IM	proteasomal protein catabolic process	44/1050	490/18723	1.43e-03	1.64e-02	44
GO:000989511	Stomach	CAG with IM	negative regulation of catabolic process	31/1050	320/18723	2.20e-03	2.24e-02	31
GO:003432911	Stomach	CAG with IM	cell junction assembly	38/1050	420/18723	2.56e-03	2.50e-02	38
GO:00421776	Stomach	CAG with IM	negative regulation of protein catabolic process	15/1050	121/18723	3.17e-03	2.95e-02	15
GO:00463282	Stomach	CAG with IM	regulation of JNK cascade	16/1050	133/18723	3.19e-03	2.96e-02	16

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SDCBP

SNV

Missense_Mutation

c.263N>T

p.Arg88Leu

p.R88L

protein_coding

tolerated(0.11)

benign(0.246)

TCGA-GM-A2DD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

fluorouracil

SDCBP

SNV

Missense_Mutation

c.574N>C

p.Asp192His

p.D192H

protein_coding

deleterious(0.03)

possibly_damaging(0.845)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

SDCBP

SNV

Missense_Mutation

rs769061064

c.893N>C

p.Ile298Thr

p.I298T

protein_coding

deleterious(0)

benign(0.197)

TCGA-DS-A0VN-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SDCBP

SNV

Missense_Mutation

c.274N>T

p.Ala92Ser

p.A92S

protein_coding

tolerated(0.54)

benign(0.042)

TCGA-JW-A69B-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.128N>G

p.Phe43Cys

p.F43C

protein_coding

tolerated(0.15)

possibly_damaging(0.831)

TCGA-F5-6814-01

Colorectum

rectum adenocarcinoma

Male

<65

I/II

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.68C>A

p.Ser23Tyr

p.S23Y

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.125C>A

p.Ala42Asp

p.A42D

protein_coding

tolerated(0.22)

benign(0.287)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.16A>G

p.Thr6Ala

p.T6A

protein_coding

tolerated_low_confidence(1)

unknown(0)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.220C>T

p.Leu74Phe

p.L74F

protein_coding

deleterious(0)

probably_damaging(0.994)

TCGA-A5-A2K5-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

SDCBP

SNV

Missense_Mutation

novel

c.886N>A

p.Glu296Lys

p.E296K

protein_coding

tolerated(0.09)

benign(0.326)

TCGA-AJ-A3EK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1